Telmisartan Influences the Antiproliferative Activity of Linoleic Acid in Human Colon Cancer Cells

References

• Gandomani HS, Yousefi SM, Aghajani M, Mohammadian-Hafshejani A, and Tarazoj AA: Colorectal cancer in the world: incidence, mortality and risk factors. Biomed Res Ther 4, 1656–1675, 2017.
   Web of Science ®Google Scholar
• Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Llorca C, et al. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 5, 263–267, 2005.
   PubMed Web of Science ®Google Scholar
• Begin ME, Das UN, Ells G, and Horrobin DE: Selective killing of human cancer cells by polyunsaturated fatty acids. Prostaglandins Leukot Med 19, 177–186, 1985.
   PubMedGoogle Scholar
• Begin ME, Ells G, and Horrobin DF: Acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst 80, 188–194, 1988.
   PubMed Web of Science ®Google Scholar
• Cantrill RC, Ells GW, DeMarco AC, and Horrobin DF: Mechanisms of the selective cytotoxic actions of certain essential fatty acids. Adv Exp Med Biol 400A, 539–544, 1997.
   PubMed Web of Science ®Google Scholar
• Fasano E, Serini S, Piccioni E, Toesca A, Monego G, et al. DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines. Biochim Biophys Acta 1822, 1762–1772, 2012.
   PubMed Web of Science ®Google Scholar
• Xia LJ and Li MG : [Effect of n-3 polyunsaturated fatty acids on proliferation and apoptosis of human colon cancer cell]. Zhonghua Wei Chang Wai Ke Za Zhi 15, 490–494, 2012.
   PubMedGoogle Scholar
• Bathen TF, Holmgren K, Lundemo AG, Hjelstuen MH, Krokan HE, et al. Omega-3 fatty acids suppress growth of SW620 human colon cancer xenografts in nude mice. Anticancer Res 28, 3717–3723, 2008.
   PubMed Web of Science ®Google Scholar
• Kuan CY, Walker TH, Luo PG, and Chen CF: Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line. J Am Coll Nutr 30, 265–273, 2011.
   PubMed Web of Science ®Google Scholar
• Hodson L, Skeaff CM, and Fielding BA: Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 47, 348–380, 2008.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yu H, Shen Y, Ni X, Shen S, et al. Polyunsaturated fatty acids trigger apoptosis of colon cancer cells through a mitochondrial pathway. Arch Med Sci 12, 1081–1094, 2015.
   Google Scholar
• Lu X, Yu H, Ma Q, Shen S, and Das UN: Linoleic acid suppresses colorectal cancer cell growth by inducing oxidant stress and mitochondrial dysfunction. Lipids Health Dis 9, 106, 2010.
   PubMed Web of Science ®Google Scholar
• Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, et al. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25, 12225–12241, 2006.
   Web of Science ®Google Scholar
• Bertz J, Dahm S, Haberland J, Kraywinkel K, Kurth B-M, et al. Spread of Cancer in Germany. Development in the Prevalence between 1990 and 2010. Robert Koch Institute, Berlin, 2010.
   Google Scholar
• Schupp M, Janke J, Clasen R, Unger T, and Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109, 2054–2057, 2004.
   PubMed Web of Science ®Google Scholar
• Kociecka BJ, Kosiecki M, and Palka JA: Telmisartan – unique among sartans, activator of PPAR-γ receptors. Farm Przeg Nauk 1, 32–36, 2009.
   Google Scholar
• Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4, 1046–1052, 1998.
   PubMed Web of Science ®Google Scholar
• Matsuyama M, Funao K, Kuratsukuri K, Tanaka T, Kawahito Y, et al. Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp Ther Med 1, 301–306, 2010.
   PubMed Web of Science ®Google Scholar
• Lee LD, Mafura B, Lauscher JC, Seeliger H, Kreis ME, et al. Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells. Oncol Lett 8, 2681–2686, 2014.
   PubMed Web of Science ®Google Scholar
• Stangier J, Su CA, and Roth W: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 28, 149–167, 2000.
   PubMed Web of Science ®Google Scholar
• Denizot F and Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 22, 271–277, 1986.
   Web of Science ®Google Scholar
• Schwab US, Callaway JC, Erkkilä AT, Gynther J, Uusitupa MI, et al. Effect of hempseed and flaxseed oils on the profile of serum lipids, serum total and lipoprotein lipid concentrations and haemostatic factors. Eur J Nutr 45, 470–477, 2006.
   PubMed Web of Science ®Google Scholar
• Baro L, Hermoso JC, Nunez MC, Jimenez-Rios JA, and Gil A: Abnormalities in plasma and red blood cell fatty acid profiles of patients with colorectal cancer. Br J Cancer 77, 1978–1983, 1998.
   PubMed Web of Science ®Google Scholar
• Sapandowski A, Stope M, Evert K, Evert M, Zimmermann U, et al. Cardiolipin composition correlates with prostate cancer cell proliferation. Mol Cell Biochem 410, 175–185, 2015.
   PubMed Web of Science ®Google Scholar
• Watkins SM, Carter LC, and German JB: Docosahexaenoic acid accumulates in cardiolipin and enhances HT-29 cell oxidant production. J Lipid Res 39, 1583–1588, 1998.
   PubMed Web of Science ®Google Scholar
• Zhang S and Wang Y: Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway. Oncol Lett 15, 5859–5864, 2018.
   PubMed Web of Science ®Google Scholar
• Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, et al. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 20, 295–300, 2008.
   PubMed Web of Science ®Google Scholar
• De Araujo RF, Leitao Oliveira AL, de Melo Silveira RF, de Oliveira Rocha HA, de Franca Cavalcanti P, et al. Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Exp Biol Med (Maywood) 240, 34–44, 2015.
   PubMed Web of Science ®Google Scholar
• Fujihara S, Morishita Ogawa L, Tadokoro T, Chiyo T, et al. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKa/mTOR pathway in vitro and in vivo. Oncotarget 8, 8536–8549, 2017.
   PubMedGoogle Scholar
• Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43, 993–1002, 2004.
   PubMed Web of Science ®Google Scholar
• Kurtz TW and Pravenec M: Antidiabetic mechanisms of ACE inhibitors and AII receptor antagonists: beyond the renin–angiotensin system. J Hypertens 22, 2253–2261, 2004.
   PubMed Web of Science ®Google Scholar
• Li J, Chen L, Yu P, Liu B, Zhu J, et al. Telmisartan exerts anti-tumor effects by activating peroxisome proliferator-activated receptor-γ in human lung adenocarcinoma A549 cells. Molecules 5, 2862–2876, 2014.
   Web of Science ®Google Scholar
• Pu Z, Zhu M, and Kong F : Telmisartan prevents proliferation and promotes apoptosis of human ovarian cancer cells through upregulating PPARγ and downregulating MMP 9 expression. Mol Med Rep 13, 555–559, 2016.
   PubMed Web of Science ®Google Scholar
• Takano S, Kubota T, Nishibori H, Hasegawa H, Ishii Y, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 28, 3593–3599, 2008.
   PubMed Web of Science ®Google Scholar
• Ohmori H, Sasahira T, Fujii K, Yi L, Shimomoto T, et al. Linoleic-acid-induced growth suppression induces quiescent cancer cell nests in nude mice. Pathobiology 75, 226–232, 2008.
   PubMed Web of Science ®Google Scholar
• Wang YL and Miao Q: To live or to die: prosurvival activity of PPARgamma in cancers. PPAR Res 2008, 209629, 2008.
   PubMed Web of Science ®Google Scholar
• Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124, 361–367, 2003.
   PubMed Web of Science ®Google Scholar
• Cesario RM, Stone J, Yen WC, Bissonnette RP, and Lamph WW: Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett 240, 225–233, 2006.
   PubMed Web of Science ®Google Scholar
• Theocharis S, Giaginis C, Parasi A, Margeli A, Kakisis J, et al. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. Dig Dis Sci 52, 2305–2311, 2007.
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, et al. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 121, 232–240, 2007.
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Vandoros GP, Sotiropoulou-Bonikou G, Kominea A, and Papavassiliou AG: NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int J Colorectal Dis 22, 57–68, 2007.
   PubMed Web of Science ®Google Scholar
• Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, and Iacopetta B: CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 9, 2898–2903, 2003.
   PubMed Web of Science ®Google Scholar
• Auwerx J and Nuclear RI: PPARγ in the gastrointestinal tract: gain or pain? Am J Physiol Gastrointest Liver Physiol 282, G581–G585, 2002.
   PubMed Web of Science ®Google Scholar
• Ogino S, Shima K, Baba Y, Nosho K, Irahara N, et al. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136, 1242–1250, 2009.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Fujii K, Yoshida K, Shimura H, Sasahira T, et al. Peritoneal metastasis inhibition by linoleic acid with activation of PPARgamma in human gastrointestinal cancer cells. Virchows Arch 448, 422–427, 2006.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Yoshida K, Shimura H, Ichiba M, Sasahira T, et al. Inhibitory effect of linoleic acid on transformation of IEC6 intestinal cells by in vitro azoxymethane treatment. Int J Cancer 118, 593–599, 2006.
   PubMed Web of Science ®Google Scholar
• Nagy L, Tontonoz P, Alvarez JG, Chen H, and Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR. Cell 93, 229–240, 1998.
   PubMed Web of Science ®Google Scholar
• Bull AW, Steffensen KR, Leers J, and Rafter JJ: Activation of PPAR gamma in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPAR gamma. Carcinogenesis 24, 1717–1722, 2003.
   PubMed Web of Science ®Google Scholar
• Lefebvre AM, Paulweber B, Fajas L, Woods J, McCrary C, et al. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J. Endocrinol 162, 331–340, 1999.
   PubMed Web of Science ®Google Scholar
• Mansen A, Guardiola-Diaz H, Rafter J, Branting C, and Gustafsson JA: Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222, 844–851, 1996.
   PubMed Web of Science ®Google Scholar
• Bull AW, Branting C, Bronstein JC, Blackburn ML, and Rafter JJ: Increases in 13-hydroxyoctadecadienoic acid (13-HODE) dehydrogenase activity during differentiation of cultured cells. Carcinogenesis 14, 2239–2243, 1993.
   PubMed Web of Science ®Google Scholar
• Bronstein JC and Bull AW: The correlation between 13-hydroxyoctadecadienoate dehydrogenase (13-HODE dehydrogenase) and intestinal cell differentiation. Prostaglandins 46, 387–395, 1993.
   PubMed Web of Science ®Google Scholar
• Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, et al. Loss-of-function mutations in PPARgamma associated with human colon cancer. Mol Cell 4, 799–804, 1999.
   Web of Science ®Google Scholar
• Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, et al. Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res 61, 5307–5310, 2001.
   PubMed Web of Science ®Google Scholar